kynurenine has been researched along with Carcinoma, Non-Small Cell Lung in 13 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study explored the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of LY3381916 monotherapy and in combination with a programmed death-ligand 1 (PD-L1) inhibitor (LY3300054) in patients with advanced solid tumors." | 3.01 | A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer. ( Bendell, J; Benhadji, KA; Doman, TN; Galvao, VR; Gandhi, L; Geeganage, S; Jalal, S; Kotecki, N; O'Neil, BH; Prenen, H; Rottey, S; Saha, A; Suriyapperuma, S; Szpurka, AM; Vuagnat, P; Wallin, J; Xia, M; Xu, X, 2021) |
| " Our results suggest that RT alters IDO-mediated immune status in NSCLC patients and that changes in this serum biomarker may be useful to predict outcomes and perhaps personalize RT dosage to improve survival." | 1.48 | IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients. ( Huang, L; Jin, JY; Jolly, S; Kong, FS; Li, L; Mellor, AL; Pi, W; Wang, W; Wu, H; Yan, L; Zang, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 8 (61.54) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, X | 1 |
| Guo, L | 1 |
| Xing, Z | 1 |
| Shi, L | 1 |
| Liang, H | 1 |
| Li, A | 1 |
| Kuang, C | 1 |
| Tao, B | 1 |
| Yang, Q | 1 |
| Wu, L | 1 |
| Wang, D | 1 |
| Chen, Y | 1 |
| Qian, M | 1 |
| Xu, X | 2 |
| Zhang, T | 1 |
| Bi, N | 1 |
| Wang, L | 2 |
| Bessede, A | 1 |
| Peyraud, F | 1 |
| Le Moulec, S | 1 |
| Cousin, S | 1 |
| Cabart, M | 1 |
| Chomy, F | 1 |
| Rey, C | 1 |
| Lara, O | 1 |
| Odin, O | 1 |
| Nafia, I | 1 |
| Guegan, JP | 1 |
| Italiano, A | 1 |
| Kober, C | 1 |
| Roewe, J | 1 |
| Schmees, N | 1 |
| Roese, L | 1 |
| Roehn, U | 1 |
| Bader, B | 1 |
| Stoeckigt, D | 1 |
| Prinz, F | 1 |
| Gorjánácz, M | 1 |
| Roider, HG | 1 |
| Olesch, C | 1 |
| Leder, G | 1 |
| Irlbacher, H | 1 |
| Lesche, R | 1 |
| Lefranc, J | 1 |
| Oezcan-Wahlbrink, M | 1 |
| Batra, AS | 1 |
| Elmadany, N | 1 |
| Carretero, R | 1 |
| Sahm, K | 1 |
| Oezen, I | 1 |
| Cichon, F | 1 |
| Baumann, D | 1 |
| Sadik, A | 1 |
| Opitz, CA | 1 |
| Weinmann, H | 1 |
| Hartung, IV | 1 |
| Kreft, B | 1 |
| Offringa, R | 1 |
| Platten, M | 1 |
| Gutcher, I | 1 |
| Xiong, J | 1 |
| Zhang, X | 1 |
| Zhang, Y | 2 |
| Wu, B | 1 |
| Fang, L | 1 |
| Wang, N | 1 |
| Yi, H | 1 |
| Chang, N | 1 |
| Chen, L | 1 |
| Zhang, J | 1 |
| Mandarano, M | 1 |
| Orecchini, E | 1 |
| Bellezza, G | 1 |
| Vannucci, J | 1 |
| Ludovini, V | 1 |
| Baglivo, S | 1 |
| Tofanetti, FR | 1 |
| Chiari, R | 1 |
| Loreti, E | 1 |
| Puma, F | 1 |
| Sidoni, A | 1 |
| Belladonna, ML | 1 |
| Kotecki, N | 1 |
| Vuagnat, P | 1 |
| O'Neil, BH | 1 |
| Jalal, S | 1 |
| Rottey, S | 1 |
| Prenen, H | 1 |
| Benhadji, KA | 1 |
| Xia, M | 1 |
| Szpurka, AM | 1 |
| Saha, A | 1 |
| Wallin, J | 1 |
| Suriyapperuma, S | 1 |
| Galvao, VR | 1 |
| Geeganage, S | 1 |
| Doman, TN | 1 |
| Gandhi, L | 1 |
| Bendell, J | 1 |
| Huang, J | 1 |
| Liu, D | 1 |
| Wang, Y | 1 |
| Liu, L | 1 |
| Li, J | 1 |
| Yuan, J | 1 |
| Jiang, Z | 2 |
| Hsiao, WW | 1 |
| Liu, H | 1 |
| Khan, I | 1 |
| Xie, Y | 2 |
| Wu, J | 1 |
| Fu, Y | 1 |
| Liao, J | 1 |
| Wang, W | 2 |
| Lai, H | 1 |
| Shi, A | 1 |
| Cai, J | 1 |
| Luo, L | 1 |
| Li, R | 1 |
| Yao, X | 1 |
| Fan, X | 1 |
| Wu, Q | 1 |
| Liu, Z | 1 |
| Yan, P | 1 |
| Lu, J | 1 |
| Yang, M | 1 |
| Cao, Y | 1 |
| Wei, H | 1 |
| Leung, EL | 1 |
| Huang, L | 1 |
| Jin, JY | 1 |
| Jolly, S | 1 |
| Zang, Y | 1 |
| Wu, H | 1 |
| Yan, L | 1 |
| Pi, W | 1 |
| Li, L | 1 |
| Mellor, AL | 1 |
| Kong, FS | 1 |
| Botticelli, A | 1 |
| Cerbelli, B | 1 |
| Lionetto, L | 1 |
| Zizzari, I | 1 |
| Salati, M | 1 |
| Pisano, A | 1 |
| Federica, M | 1 |
| Simmaco, M | 1 |
| Nuti, M | 1 |
| Marchetti, P | 1 |
| Moon, PK | 1 |
| Tran, S | 1 |
| Minhas, PS | 1 |
| Iversen, TZ | 1 |
| Engell-Noerregaard, L | 1 |
| Ellebaek, E | 1 |
| Andersen, R | 1 |
| Larsen, SK | 1 |
| Bjoern, J | 1 |
| Zeyher, C | 1 |
| Gouttefangeas, C | 1 |
| Thomsen, BM | 1 |
| Holm, B | 1 |
| Thor Straten, P | 1 |
| Mellemgaard, A | 1 |
| Andersen, MH | 1 |
| Svane, IM | 1 |
| Engin, AB | 1 |
| Ozkan, Y | 1 |
| Fuchs, D | 1 |
| Yardim-Akaydin, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer[NCT03562871] | Phase 1/Phase 2 | 109 participants (Actual) | Interventional | 2018-08-22 | Completed | ||
| IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.[NCT01219348] | Phase 1 | 14 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for kynurenine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cel | 2021 |
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Disea | 2014 |
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Disea | 2014 |
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Disea | 2014 |
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Disea | 2014 |
11 other studies available for kynurenine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D Ligand via ADAM10.
Topics: ADAM10 Protein; Amyloid Precursor Protein Secretases; Animals; Carcinoma, Non-Small-Cell Lung; Down- | 2022 |
Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn | 2022 |
Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non-Small Cell Lung Cancer.
Topics: B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynuren | 2023 |
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Dioxygenases; Head and Neck Neoplasms; Humans; Immunologic | 2023 |
Aryl hydrocarbon receptor mediates Jak2/STAT3 signaling for non-small cell lung cancer stem cell maintenance.
Topics: Adult; Aged; Animals; Azo Compounds; Basic Helix-Loop-Helix Transcription Factors; Carcinogenesis; C | 2020 |
Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, | 2021 |
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Deat | 2022 |
IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; C | 2018 |
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Female; Humans | 2018 |
Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Indoleamine-Py | 2019 |
Increased tryptophan degradation in patients with bronchus carcinoma.
Topics: Blood Sedimentation; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indoleamine | 2010 |